HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

A Nelde; JS Walz; DJ Kowalewski; H Schuster; OO Wolz; JK Peper; YC Gloria; Ton Langerak; Alice Muggen; R Claus; I Bonzheim; F Fend; HR Salih; L Kanz; HG Rammensee; S Stevanovic; ANR Weber

doi:10.1080/2162402x.2016.1219825

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

A Nelde
, JS Walz
, DJ Kowalewski
, H Schuster
, OO Wolz
, JK Peper
, YC Gloria
, Ton Langerak
, Alice Muggen
, R Claus
, I Bonzheim
, F Fend
, HR Salih
, L Kanz
, HG Rammensee
, S Stevanovic
, ANR Weber

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

31 Citations (Scopus)

42 Downloads (Pure)

Original language	Undefined/Unknown
Journal	OncoImmunology
Volume	6
Issue number	3
DOIs	https://doi.org/10.1080/2162402x.2016.1219825
Publication status	Published - 2017

Research programs

EMC MM-02-72-01

Access to Document

10.1080/2162402x.2016.1219825

REPUB_98395.pdfFinal published version, 1.54 MB

http://hdl.handle.net/1765/98395

Cite this

Nelde, A., Walz, JS., Kowalewski, DJ., Schuster, H., Wolz, OO., Peper, JK., Gloria, YC., Langerak, T., Muggen, A., Claus, R., Bonzheim, I., Fend, F., Salih, HR., Kanz, L., Rammensee, HG., Stevanovic, S., & Weber, ANR. (2017). HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology, 6(3). https://doi.org/10.1080/2162402x.2016.1219825

@article{283b686e2bdb496aa25ec40dba0c5e68,

title = "HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy",

author = "A Nelde and JS Walz and DJ Kowalewski and H Schuster and OO Wolz and JK Peper and YC Gloria and Ton Langerak and Alice Muggen and R Claus and I Bonzheim and F Fend and HR Salih and L Kanz and HG Rammensee and S Stevanovic and ANR Weber",

year = "2017",

doi = "10.1080/2162402x.2016.1219825",

language = "Undefined/Unknown",

volume = "6",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor \& Francis Ltd (UK)",

number = "3",

}

Nelde, A, Walz, JS, Kowalewski, DJ, Schuster, H, Wolz, OO, Peper, JK, Gloria, YC, Langerak, T, Muggen, A, Claus, R, Bonzheim, I, Fend, F, Salih, HR, Kanz, L, Rammensee, HG, Stevanovic, S & Weber, ANR 2017, 'HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy', OncoImmunology, vol. 6, no. 3. https://doi.org/10.1080/2162402x.2016.1219825

TY - JOUR

T1 - HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

AU - Nelde, A

AU - Walz, JS

AU - Kowalewski, DJ

AU - Schuster, H

AU - Wolz, OO

AU - Peper, JK

AU - Gloria, YC

AU - Langerak, Ton

AU - Muggen, Alice

AU - Claus, R

AU - Bonzheim, I

AU - Fend, F

AU - Salih, HR

AU - Kanz, L

AU - Rammensee, HG

AU - Stevanovic, S

AU - Weber, ANR

PY - 2017

Y1 - 2017

U2 - 10.1080/2162402x.2016.1219825

DO - 10.1080/2162402x.2016.1219825

M3 - Article

SN - 2162-4011

VL - 6

JO - OncoImmunology

JF - OncoImmunology

IS - 3

ER -